$PRTK News
Last published 1y ago
- 1y agoPRTKParatek Pharmaceuticals, Inc. - Appeal, AffirmedUS Patent Trial and Appeal Board
- 1y agoPRTKParatek Pharmaceuticals, Inc. - Appeal, AffirmedUS Patent Trial and Appeal Board
- 3y agoPRTKGurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.GlobeNewswireCAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings") announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc.
- 3y agoPRTKParatek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/SGlobeNewswireBOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for
- 3y agoPRTKSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/SGlobeNewswireBOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 3y agoPRTKMicrobiome Effect of Omadacycline on Healthy Volunteers - NCT06030219ClinicalTrials.govMicrobiome changes
- 3y agoPRTKLeading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo HoldingsGlobeNewswireBOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel
- 3y agoPRTKParatek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 MillionGlobeNewswire-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and
- 3y agoPRTKParatek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo HoldingsGlobeNewswireTransaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on Achievement of a Commercial
- 3y agoPRTKNexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point CapitalPR NewswirePlans to Investigate All Records to Ensure Board Did Not Breach Fiduciary Duty DALLAS, July 11, 2023 /PRNewswire/ -- NexPoint Event Driven Fund today issued a demand letter to the Board of Directors of Paratek
- 3y agoPRTKParatek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary AnthraxGlobeNewswire-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in early 2024 BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek
- 3y agoPRTKParatek Pharmaceuticals Acknowledges Receipt of NexPoint LetterGlobeNewswireBOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for
- 3y agoPRTKNexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point CapitalPR NewswireIntends to Withhold Its Votes Against All Three Board Members Up for Election at the Annual Meeting Citing the Board's Failure to Hold Management Accountable for Years of Underperformance Plans to Carefully
- 3y agoPRTKEuropean Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseGlobeNewswireBOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for
- 3y agoPRTKPRTK Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Paratek Pharmaceuticals to Gurnet Point Capital and Novo HoldingsGlobeNewswireMONSEY, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the $2.15 per share in cash, plus a contingent value right (CVR), at which Paratek
- 3y agoPRTKParatek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023GlobeNewswireBOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for
- 3y agoPRTKParatek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo HoldingsGlobeNewswireTransaction Provides Paratek Shareholders with Immediate Value and Liquidity Reflects Potential Value of $3.00 per Share of Common Stock, Including Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of
- 3y agoPRTKParatek Pharmaceuticals, Inc. (PRTK) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoPRTKParatek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 MillionGlobeNewswire-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158
- 3y agoPRTKParatek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9GlobeNewswireBOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report
- 3y agoPRTKParatek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023GlobeNewswireBOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for
- 3y agoPRTKParatek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 MillionGlobeNewswire-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous Mycobacteria
- 3y agoPRTKParatek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16GlobeNewswireBOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to
- 3y agoPRTKParatek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireBOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for
- 3y agoPRTKParatek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for
- 3y agoPRTKZLABParatek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)GlobeNewswireBOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that China's National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of
- 3y agoPRTKParatek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield ContractGlobeNewswireTotal Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax
- 3y agoPRTKParatek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the BoardGlobeNewswireBOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company's independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead
- 3y agoPRTKParatek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShieldGlobeNewswire100% Survival Rate in Anthrax-infected Rabbits Treated with OmadacyclineTotal Revenue Recognition to Paratek of $38.1 Million BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)
- 3y agoPRTKParatek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for
- 3y agoPRTKParatek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewswireBOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for
- 4y agoPRTKParatek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 MillionGlobeNewswire-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021 -- Initiated Rabbit Pilot Efficacy Study for the
- 4y agoPRTKParatek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for
- 4y agoPRTKParatek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare ConferenceGlobeNewswireBOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for
- 4y agoPRTKParatek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield ContractGlobeNewswireBOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone follows a
- 4y agoPRTKParatek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3GlobeNewswireBOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report
- 4y agoPRTKParatek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022GlobeNewswireHighlights include data from non-clinical and microbiology programs and real-world patient use BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage
- 4y agoPRTKParatek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other
- 4y agoPRTKParatek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)GlobeNewswireBOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other
- 4y agoPRTKParatek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other
- 4y agoPRTKParatek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireBOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other
- 4y agoPRTKEffects of Intravenous (IV) Omadacycline on Gut Microbiome - NCT05515562ClinicalTrials.govChange in gut microbiota concentrations
- 4y agoPRTKParatek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 MillionGlobeNewswire-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021 -- Company Reiterates Full Year 2022 Financial Guidance BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE)
- 4y agoPRTKParatek Pharmaceuticals (PRTK) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsPRTK earnings call for the period ending June 30, 2022.
- 4y agoPRTKParatek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other
- 4y agoPRTKParatek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022GlobeNewswireBOSTON, July 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:30 p.m. ET to report its financial results for the secon
- 4y agoPRTKParatek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireBOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other
- 4y agoPRTKParatek Pharmaceuticals' NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)GlobeNewswire-- Phase 2b Study in MAB Pulmonary Infections Ongoing and Enrolling as Planned -- Nonclinical Studies in MAC Initiating BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced the U.S. Food and Drug A
- 4y agoPRTKParatek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireBOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other
- 4y agoPRTKParatek Pharmaceuticals to Present at the Jefferies 2022 Healthcare ConferenceGlobeNewswireBOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other p